GeneCare Research Institute

What GeneCare Research Institute does

GeneCare Research Institute Co., Ltd. (株式会社ジーンケア研究所) is a pre-revenue Japanese biotechnology venture founded in December 2000 by researchers from AGENE Research Institute, headquartered in Kamakura, Kanagawa. The company focuses on siRNA-based drug discovery targeting RecQ family DNA helicases (RECQL1, WRN, BLM, RECQL4) to induce cancer cell-selective apoptosis by disrupting DNA copying during cell division. Its lead candidate is the RECQL1-siRNA/LNP formulation, a nucleic acid medicine delivered via lipid nanoparticles (LNP) and administered via a novel localized intraperitoneal injection method designed to treat peritoneal dissemination cancers, particularly recurrent ovarian cancer and colorectal cancer with ascites. The company has also developed tissue-specific delivery conjugate siRNA technology under AMED funding and has historically explored anti-inflammatory applications through its 2001 acquisition of UP Science's project.

GeneCare operates as a B2B R&D venture with no direct product distribution. Direct customers are pharmaceutical companies and clinical laboratory companies, accessed through licensing deals, co-development partnerships, and R&D collaboration contracts. Revenue mechanics rely on (1) R&D collaboration contracts (historically with Toshiba and four domestic pharma companies; more recently with Solasia Pharma via a July 2020 option rights agreement), (2) licensing royalties anchored by an exclusive license and option agreement with Alnylam Pharmaceuticals (January 2005) covering RecQ helicase clinical applications, and (3) non-dilutive funding from Japanese government programs including AMED, JST, NEDO, and METI. The company is led by President and Representative Director Naoya Takahashi (appointed March 2016), with founder Dr. Yasuhiro Furuichi having retired in March 2021.

The company's competitive positioning rests on a novel mechanism of action (selective cancer cell killing by exploiting weaker DNA checkpoint mechanisms in cancer cells), a differentiated DDS approach for hard-to-treat peritoneal cancers, and foundational RNAi patent rights from Alnylam. As of available data, the company had approximately 5 employees, registered capital of ¥10.026M (October 2016, down from a ¥991.3M peak in May 2007), and had progressed through PMDA consultation (April 2017) and the National Cancer Center Medical Venture Consultation program (September 2017, first case). A Phase 1 clinical trial is estimated to require approximately ¥1.5 billion in funding, which is not yet disclosed as secured.

Name

GeneCare Research Institute

Legal name

GeneCare Research Institute Co., Ltd.

Website

https://genecare.co.jp

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

GeneCare Research Institute is a pre-revenue Japanese biotech venture developing siRNA-based anticancer drugs that target RecQ helicases, with a lead RECQL1-siRNA/LNP candidate for localized intraperitoneal treatment of peritoneal dissemination cancers, out-licensed or co-developed with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Oncology siRNA Therapeutics / Cancer Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)

Keywords

• SiRNA drug discovery
• Oncology biotechnology
• Nucleic acid medicine
• Drug delivery systems
• Cancer therapeutics

Headquarters

HQ city

Kamakura

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. R&D Collaboration Contracts with Pharmaceutical Companies: GeneCare enters into research and development contracts with pharmaceutical companies, providing access to its siRNA technology platform and pipeline candidates. Direct customers are pharma and clinical laboratory companies.
2. RNAi Basic Patent Licensing (Alnylam): In January 2005, GeneCare concluded a license and option agreement with Alnylam Pharmaceuticals (USA) for exclusive use of RecQ helicase-related clinical applications. This provides GeneCare access to foundational RNAi patents for its drug development.
3. Government Grants and Subsidized R&D Projects: GeneCare participates in government-funded research programs including AMED, JST, NEDO, and other ministry programs, which provide non-dilutive funding for specific R&D projects. Projects include the 5-year national project for C hepatitis/liver cancer prevention, AMED conjugate siRNA program, JST commissioned development, and NEDO innovation promotion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

GeneCare Research Institute is a pre-revenue Japanese biotechnology venture that discovers and develops siRNA-based anticancer nucleic acid medicines. Its lead candidate is RECQL1-siRNA/LNP, a lipid nanoparticle-formulated small interfering RNA that silences the RECQL1 DNA repair helicase to induce selective cell death in cancer cells, intended for the treatment of peritoneal dissemination cancers (recurrent ovarian cancer, colorectal cancer with ascites) via a proprietary intraperitoneal local administration method. The company monetizes its platform through licensing deals, co-development partnerships, R&D service contracts with pharmaceutical companies, and government research grants, rather than through direct product sales.

Product overview

GeneCare Research Institute is a biotechnology venture company focused on siRNA-based anticancer drug development. The company operates as a single-product research and development organization, with its primary offering being the RECQL1-siRNA/LNP formulation. This nucleic acid medicine targets cancer cells by disrupting the RecQL1 DNA repair helicase, inducing cell cycle arrest and apoptosis specifically in cancer cells. The company leverages proprietary DDS (Drug Delivery System) technology and is developing intraperitoneal administration methods for treating peritoneal dissemination cancers, particularly ovarian cancer. All operations center on advancing this therapeutic candidate through preclinical and clinical development stages.

Differentiator

Problem solved

Functional benefit

Products and services

• RECQL1-siRNA/LNP Anticancer Agent An siRNA-based nucleic acid medicine targeting the RECQL1 DNA repair helicase, formulated with lipid nanoparticle (LNP) Drug Delivery System (DDS) technology for selective induction of cancer cell death. Designed for the treatment of peritoneal dissemination cancers (recurrent ovarian cancer, colorectal cancer with ascites) via a proprietary intraperitoneal local administration method that delivers high local concentration while avoiding the liver accumulation limitation of intravenous LNP administration. Sold/in-licensed to pharmaceutical companies for co-development rather than marketed directly to end customers.

Quantifiable outcome

• RECQL1-siRNA demonstrated anticancer activity in mouse xenograft models, inducing mitotic cell death in cancer cells and increasing sensitivity to camptothecin chemotherapy.
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Alnylam Pharmaceuticals, Inc.coreTechnology or Integration · 1 January 2005GeneCare concluded a license and option agreement with Alnylam Pharmaceuticals (USA) in January 2005 to exclusively use the RNAi basic patent portfolio for RecQ helicase-related clinical applications. This provides GeneCare with foundational intellectual property rights essential for developing siRNA-based anticancer drugs, covering the core technology platform.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Emerging players

• Sirnaomics: Clinical-stage siRNA therapeutics company focused on oncology and fibrosis using proprietary PNP and GalNAc delivery platforms. Closely comparable to GeneCare in stage, mechanism focus, and partner-driven commercialization model.

Direct peers

• Wave Life Sciences: Clinical-stage nucleic acid therapeutics company developing siRNA and stereopure antisense oligonucleotides. Shares GeneCare's RNA-based approach to oncology and rare disease, with comparable platform-stage maturity but stronger public-market capitalization.
• Dicerna Pharmaceuticals (Novo Nordisk): siRNA therapeutics company acquired by Novo Nordisk in 2021, known for GalXC™ platform. Competes directly with GeneCare in developing siRNA drugs for cancer and rare diseases, with substantially greater resources and clinical maturity.
• Alnylam Pharmaceuticals: Global leader in siRNA therapeutics and GeneCare's RNAi patent licensor (2005 agreement). Both companies develop siRNA-based drugs using LNP delivery; Alnylam's much larger pipeline (Onpattro, Givlaari, Oxlumo) serves as the reference platform for GeneCare's technology.
• Arrowhead Pharmaceuticals: Clinical-stage siRNA therapeutics company with multiple oncology programs using proprietary TRiM™ delivery platform targeting cancer, similar to GeneCare's localized delivery approach. Comparable business model focused on out-licensing candidates to larger pharma partners.

Others

• Nitto Denko Avecia: CDMO specializing in oligonucleotide and RNA therapeutic manufacturing, including LNP formulation services. Relevant as a potential manufacturing partner for GeneCare's siRNA/LNP programs as the company advances toward clinical trials.

Broad incumbents

• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide (ASO) therapeutics with broad pipeline and approved products (Spinraza, Tegsedi). Provides a broader nucleic acid therapeutics comparison point for GeneCare's siRNA approach, though Ionis operates at much greater scale.

Regional players

• Solasia Pharma: Japanese specialty pharmaceutical company that entered into an option rights agreement with GeneCare in July 2020 for the RECQL1-siRNA program. Operates as a regional oncology-focused pharma and serves as GeneCare's most direct commercialization partner within Japan.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneCare Research Institute